Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis by Gilbert, R et al.
RS
s
R
a
b
a
A
R
A
A
K
U
S
O
S
A
B
h
n
o
o
c
p
s
i
r
b
t
p
o
r
c
a
f
l
a
2
lPorto Biomed. J. 2017;2(2):33–39
Porto  Biomedical  Journal
ht tp : / / www.por tobiomedica l journa l .com/
eview  article
tatins  as  anti-inﬂammatory  agents:  A  potential  therapeutic  role  in
ight-threatening  non-infectious  uveitis
ose  Gilberta,b,∗, Ahmed  Al-Janabia,b, Oren  Tomkins-Netzera,b, Sue  Lightmana,b
Moorﬁelds Eye Hospital, London, UK
University College London (UCL) Institute of Ophthalmology, London, UK
 r  t i  c  l  e  i  n  f  o
rticle history:
eceived 5 October 2016
ccepted 5 January 2017
vailable online 1 March 2017
a  b  s  t  r  a  c  t
In addition  to the  known  lipid-lowering  effects,  statins  are  now  widely  accepted  to  have anti-
inﬂammatory  and  immunomodulatory  effects.  Adjunctive  use of statins  has  proven  beneﬁcial  in the
context  of a wide  range  of  inﬂammatory  diseases,  including  rheumatoid  arthritis.  Evidence  also  suggests
that  statins  may  also  have  utility  in  the  management  of uveitis,  a form  of sight  threatening  inﬂammationeywords:
veitis
tatins
cular inﬂammatory disease
teroid-sparing agents
which  occurs  in  the  eye.  In  this  article,  we  outline  our  rationale  behind  a  clinical  trial  of simvastatin  as a
steroid-sparing  agent  in  uveitis,  to which  patient  recruitment  started  last year.  Potential  risks  associated
with  the  clinical  use of statins,  including  putative  effects  on the  eyes,  are  discussed.
©  2017  PBJ-Associac¸a˜o  Porto  Biomedical/Porto  Biomedical  Society.  Published  by  Elsevier  Espan˜a,
S.L.U.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/nti-inﬂammatory
ackground
Uveitis could be “the most important eye disease you’ve never
eard of”. It is a signiﬁcant but largely unrecognised cause of perma-
ent visual impairment worldwide. Uveitis denotes inﬂammation
f the uvea, which is the highly vascular pigmented middle layer
f the eye, between the sclera and the retina. The uveal tract is
omposed of the iris and ciliary body, anteriorly, and the choroid,
osteriorly.1 However, the term “uveitis” has now become almost
ynonymous in ophthalmic clinical practice with any inﬂammation
nvolving structures inside the eye, including vitreous gel and the
etina (Figs. 1 and 2).
In the Western world, the current incidences of uveitis vary
etween 38 and 200 per 100,000.2 Many cases are chronic, and lead
o numerous sight-threatening complications, including decom-
ensation/degeneration of the cornea (the clear anterior window
f the eye); cataract (opacity of the crystalline lens of the eye);
aised intraocular pressure; glaucoma (optic neuropathy with a
haracteristic peripheral visual defect); and retinal pathology (such
s macular oedema and retinal detachment), which affects retinal
unction (Fig. 3).Around 10–15% of all causes of vision loss and 20% of cases
egally recognised as “blindness” are attributed to uveitis.3 It can
ffect people of all ages but occurs most frequently in the working
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age population (20–50 years), where the socio-economic impact
of visual impairment is thought to be comparable to diabetic
retinopathy.4 Visual loss in uveitis has been historically underes-
timated due of the lack of data concerning the incidence of sight
threatening complications. A recent study conducted by our group
on the long-term clinical outcomes of patients attending a tertiary
centre uveitis clinic indicates that the incidence of visual impair-
ment in these patients is 19%.5
In the majority of cases, the aetiology of inﬂammation in
uveitis is non-infectious and idiopathic. Non-infectious uveitis has
been classically described as an autoimmune disease, mediated by
Th1 and Th17 subsets of self-reactive CD4 T-lymphocytes, which
secrete “signature” pro-inﬂammatory cytokines, speciﬁcally, inter-
feron (IFN)- and interleukin (IL)-17. Our understanding of the
pathogenesis of non-infectious uveitis has been facilitated by a
mouse model of experimental autoimmune uveitis (EAU), in which
a soluble retinal antigen and interphotoreceptor retinoid-binding
protein (IRBP) are injected to create an immune response (Fig. 4).6
As with other forms of autoimmune inﬂammatory disease,
the mainstay treatment of non-infectious uveitis is high dose
corticosteroids with additional second-line immunosuppressive
agents (such as mycophenolate, methotrexate, azathioprine or
cyclosporine A), as required to reduce the corticosteroid doses
and associated side effects. Corticosteroids and other immune-
modulating treatments are not curative but rather suppress the
immune system, thereby reducing the ocular tissue damage and
detrimental consequences on vision, which result from immune
system hyperactivity. The ocular side effects of corticosteroids
d by Elsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND
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sig. 1. Clinical retinal photography image showing the normal appearance of the 
entral  30 degrees of vision and (c) retinal blood vessels.
nclude raised intraocular pressure, glaucoma and cataracts. In
ddition to the risk of infection associated with immunosuppres-
ion, given systemically, these drugs together have signiﬁcant side
ffects which include hypertension, diabetes, liver dysfunction,
steoporosis and potential malignancy. In other chronic immune-
elated inﬂammatory conditions, such as rheumatoid arthritis (RA)
nd systemic lupus erythematosus (SLE), it is known that there is an
ssociated increased risk of premature atherogenesis and cardio-
ascular disease (CVD).7,8 Furthermore, prescription corticosteroid
se, itself, is associated with increased long-term CVD risk (Fig. 5).9
The burden of the current immunosuppressive drugs (costs, side
ffects and monitoring), plus the often relapsing and remitting
ourse of inﬂammatory disease, are a major problem for patients,
linicians and ophthalmic services in the Western world. As we con-
inue to learn more about the different mechanisms and biological
athways leading to ocular inﬂammation, newer biological anti-
nﬂammatory therapeutic approaches are being developed and
ested.10 However, these therapies are expensive and the long-term
afety and efﬁcacy are not known. An alternative approach is drug
e-positioning, that is, application of known drugs and compounds
o treat new indications.
tatins as anti-inﬂammatory agents
Statins have been used for decades as a therapy for hypercholes-
erolemia, in order to reduce the risk of developing atherosclerosis
nd cardiovascular disease. They are pharmacological inhibitors
f the conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA),
nto L-mevalonate, the rate-limiting step in cholesterol synthe-
is, by competitive blocking of the active site of the enzyme with the following structures: (a) optic disc, (b) macular area (responsible for the
HMG-CoA reductase. Blockade of the mevalonate pathway thereby
affects cholesterol production and, ultimately, reduces serum low-
density lipoprotein (LDL) cholesterol levels, which are associated
with increased risk of cardiovascular disease (Fig. 6).
In the cholesterol synthesis pathway, mevalonate is the pre-
cursor not only for cholesterol, but also for many non-steroidal
isoprenoid compounds. The mevalonate pathway plays a vital role
in various cellular functions, including cell signalling, cell differen-
tiation and proliferation, myelination, cytoskeleton dynamics, and
endocytotic/exocytotic transport.11 There is compelling evidence
that statins have pleiotropic effects, independent of choles-
terol lowering, and this is due to their role in induction of
post-transcriptional modiﬁcations of important isoprenoid inter-
mediates downstream of mevalonate.12 This process is known as
“prenylation” and affects numerous signal transduction molecules
in inﬂammatory, as well as vascular and myocardial pathways. The
small guanine-triphosphate (GTP)-binding proteins, which include
Rho, Rac and Ras, are an important group of proteins involved in
the intracellular signalling pathways modulated by statins. These
small GTP proteins regulate pro-atherogenic, pro-inﬂammatory
pathways and are activated by isoprenylation.13 Rho proteins, in
particular, are involved in the expression of pro-inﬂammatory
cytokines. A study proposed that simvastatin reduced the activity
of RhoA, which is involved in tumour necrosis factor (TNF)--
induction and the activation of nuclear factor (NF)-B and cytokine
secretion.14Early evidence of the anti-inﬂammatory effects of statins derives
from studies on patients with CVD. An important study that
initially addressed this was  the PRINCE (pravastatin inﬂamma-
tion/CRP evaluation) randomised controlled trial (RCT), where
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Vitreous condensations Multiple pale chorioretinal lesions
Vitreous haze and “snowballs” Punctate macular atrophy
Fig. 2. Clinical retinal photography images illustrating how sight-threatening noninfectious uveitis might manifest in the eye. Inﬂammation appears as pale white/yellow
chorio-retinal spots and/or haziness with “ﬂoaters” in the vitreous gel, which ﬁlls the posterior chamber of the eye. Inﬂammation may  lead to visual loss and blindness by
causing pale, atrophic scarring of the retina, with exposure of the underlying black retinal pigment epithelium.
Fig. 3. Complications of corticosteroid therapy: posterior subcapsular cataracts (a subtype of cataract/opacity of the crystalline lens, typically seen in patients on long-term
corticosteroids).
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lFig. 4. Murine retinal histology sections showing cross-secti
tatin use resulted in reduction of C-reactive protein (CRP) levels
n these patients.15 CRP is a systemic inﬂammatory marker, pro-
uced by the liver under the direct inﬂuence of IL-6. This effect
n CRP by statins was shown to be independent of the cholesterol
owering effect.16,17 Clinical studies have also demonstrated thef: (a) normal mouse retina and (b) EAU mouse model retina.
anti-inﬂammatory effects of statins in RA. In the randomised con-
trolled Trial of Atorvastatin in Rheumatoid Arthritis (TARA), statins
had signiﬁcant effect on reducing disease activity. The authors
noted that the effect of atorvastatin could prove beneﬁcial in the
context of disease-modifying therapy combination design, in which
36 R. Gilbert et al. / Porto Biomed. J. 2017;2(2):33–39
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Fig. 6. Statins and the cholesterol synthesis pathway.
tatins offer both vascular protective and adjunctive immunomod-
latory potential.18 Nagashima et al. showed that statins induced
otent inhibition via protein geranylgeranylation (another form of
renylation) of pro-inﬂammatory cytokine production (TNF-,  IL-
, IL-6 and IL-8) by rheumatoid synovial cells.19 Further studies
ave demonstrated the anti-inﬂammatory effect of statins in other
linical contexts. Statins decrease the recruitment of monocytes
nd T-cells into the arterial wall and inhibit T-cell activation and
roliferation in vitro, leading to the belief that the immunomod-
latory effects of statins may  be of help in recipients of organ
ransplantation.20 A landmark study then showed that statins
ecreased rejection rate and prolonged survival of cardiac trans-
lant patients.21 Simvastatin was also shown to have a positive
ffect on brain atrophy rate in secondary progressive multiple scle-
osis. An RCT in which patients had 80 mg  simvastatin in additionts of corticosteroids.
to disease modifying agents, showed 43% reduction in the annual
rate of brain atrophy.22 However, other studies conducted on early
stage multiple sclerosis using simvastatin or atorvastatin showed
no effect on relapse rate or MRI  appearance.23,24
A study from our ocular immunology group has shown
that statins can synergise with conventional immunosuppress-
ive agents to modulate T-cell proliferation and pro-inﬂammatory
cytokine production.25 Other speciﬁc effects of statins on the
immune system include reduction in antigen presentation via inhi-
bition of IFN-, which is necessary for the induction of major
histocompatibility complex (MHC) class II expression, and inhi-
bition of T-cell differentiation into the pro-inﬂammatory Th1
sub-type (again via protein geranylgeranylation).26–28 One  of the
key issues underlying the pathogenesis of autoimmune disease is
the process by which systemic immune cells “home” to target organ
sites of inﬂammation. The mechanism for this involves leucocyte
migration, adhesion to vascular endothelial cells and the expression
of self-adhesion molecules. The integrin lymphocyte function asso-
ciated antigen-1, which binds to intercellular adhesion molecule-1
(ICAM-1) is altered by statins, leading to inhibition of lymphocytes
adhesion and activation.29 Reduction in leucocyte inﬁltration of
the eye is a consistent ﬁnding in autoimmune uveitis treated with
statins.12
A further research focus in ocular immunology relates to the
investigation of the role of systemic phenotypically categorised
CD4+CD25+FoxP3+ T-regulatory cells (Tregs) in the reduction in
ocular inﬂammation and induction of clinical remission of uveitis.
Tregs are considered to be the “guardians of peripheral tolerance”
and their role in the prevention of autoimmune diseases such as
SLE and RA is well recognised. In these diseases it appears that
there has been a failure of Tregs to keep pace with the activa-
tion of effector cells, resulting in an inability to resist ensuing
inﬂammation.30 In patients with active uveitis compared with
healthy controls, decreased peripheral blood levels of Tregs have
been found, with levels being signiﬁcantly upregulated during dis-
ease remission.31 We  have shown recently that in ocular Bec¸ hets, a
systemic inﬂammatory disease, Treg levels are increased by treat-
ment with the immunomodulating therapy, pegylated interferon-
(pegIFN-), and the increased levels of Tregs are still detectable at
12 months, 6 months after cessation of therapy. In animal models,
the immunosuppressive effect of simvastatin has been attributed
partially to its ability to promote the generation of T-regs.33 Studies
have elucidated the myriad ways in which statins modulate Treg
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iology, which include inﬂuencing the microenvironment required
or the induction and maintenance of Tregs; directly enhancing the
nduction of Tregs; inﬂuencing the migration of Tregs and hom-
ng of Tregs to inﬂamed tissues; and inhibiting the induction of
ro-inﬂammatory Th1 and Th17 T-cell subtypes (Fig. 7).34
ationale for a clinical trial of simvastatin in uveitis patients
Our group and others have reported on the pleiotropic effect of
imvastatin, highlighting its anti-inﬂammatory effect and poten-
ial use as a steroid-sparing agent. Patients with uveitis are often
equired to adhere to steroid therapy for a long periods of time.
t is, of course, preferable for these corticosteroids to at the low-
st effective dose necessary to keep the inﬂammatory drive under
ontrol. However, high initial loading doses of corticosteroids are
ften the best option for rapid control of inﬂammation in the case
f a uveitic relapse. Inﬂammatory ﬂare-ups are inevitable in most
orms of non-infectious autoimmune uveitis, which tend to follow
 relapsing and remitting disease course.
As previously mentioned, corticosteroids are associated with a
ide array of adverse effects including hypercholesterolemia and
therosclerosis. As a result, patients are at risk of having ischaemic
eart disease or stroke in the long-term, even if they tolerate sys-
emic steroid therapy in the short-term. Statins provide beneﬁt to
hose patients at risk by reducing high cholesterol levels and may
onfer additional anti-inﬂammatory effects. A retrospective popu-
ation based case control-study showed that the likelihood (odds)
f developing uveitis among statin users were half than that of
atients not taking statins.35 Not all statins have the same activity
n modulating the inﬂammation, for example atorvastatin appears
ess efﬁcacious in retinal inﬂammatory disease while lovastatin
emonstrated a better effect.36 Our group has shown that simvas-
atin, in particular, has a unique ability to suppress the activity of
nﬂammatory cells.25
The blood-brain barrier and blood-ocular barrier demonstrate
imilar transport and permeation characteristics.37 A study com-
ared the ability of three statins (simvastatin, lovastatin and
ravastatin) in their ability to cross the blood brain barrier and to
lter gene expression in mice.38 Simvastatin, which is a lipophilic
ompound was able to cross the blood brain barrier, and was
ound in cerebral cortex of mice in vivo. Furthermore, simvas-
atin showed greatest effect on gene expression when compared to
ovastatin and pravastatin. Simvastatin was able to alter 23 addi-
ional genes involved in cell growth, signalling and trafﬁcking. Of
articular importance was the expression of genes involved ind. J. 2017;2(2):33–39 37
apoptotic pathways, which could be a fundamental contributor
to immunosuppression.38 In the EAU mouse model, statins were
shown to suppress leucocytes inﬁltration to the retina and decrease
vascular leakage.36 It is thought simvastatin might be able to exert a
similar local immunomodulatory effect on ocular tissue in humans.
With this in mind, we are currently conducting the ﬁrst RCT to
assess such effects in patients with uveitis: “Can Simvastatin Sig-
niﬁcantly Reduce the Amount of Immunosuppressive Medication
Required by Patients With Sight Threatening Uveitis? A Phase 2b,
Single Site, Randomised, Placebo Controlled, Double Blinded Trial”
(ID NCT02252328, http://www.clinicaltrials.gov). The primary out-
come for this RCT is the change in dose (mg) of prednisolone
after 12 months of treatment. The reduction in the corticosteroid
(prednisolone) dose will be a surrogate measure for the control of
inﬂammation. The efﬁcacy of statins as anti-inﬂammatory agents
will be assessed by measuring the reduction of oral steroid dose
required by uveitis patients, with concomitant use of simvastatin.
Patient recruitment to this trial is currently ongoing.
Potential risks associated with clinical use of statins
Statins are generally well-tolerated and safe and, moreover,
are considered among the safest drugs used in medical practice.39
This is supported by long-term follow-up studies of randomised
clinical trials in the management of hypercholesterolaemia, ran-
ging from 10 to 15 years.40,41 The risk for mortality or permanent
organ damage associated with statins is almost entirely related
to rhabdomyolysis, that is, drug-induced damage to muscle tis-
sue that leads elevation of creatine kinase (CK), myoglobin protein
release into the bloodstream and potential renal failure. RCT-
reported case fatality rate from hospitalized rhabdomyolysis was
about 1 in 10.5.42 Thus mortality caused by statin treatment is
rare. Statins cause myopathy, as well as rhabdomyolysis. Myopa-
thy is deﬁned as diffuse muscle symptoms (pain, tenderness,
weakness) with elevated CK, sufﬁcient to consult a physician
but insufﬁcient to warrant hospital admission. It is probable that
myopathy and rhabdomyolysis constitute a spectrum of the same
muscle disorder, rhabdomyolysis being the more severe, charac-
terised by a higher CK level and myoglobinuria.43 It is common
for patients who  are started on statins to develop symptoms of
muscle soreness, however, in many cases this resolves sponta-
neously. Due to the aforementioned risk of serious statin-induced
muscle damage and mortality, it is imperative to monitor CK levels
in these patients. Apart from muscle disease, toxicity attributable
to statins, if it occurs at all, is rare. Although statin treatment
may result in substantial increases in serum liver enzyme levels
(transaminase levels, alanine aminotransferase and/or aspartate
aminotransferase, in 0.3–3% of patients in a dose-dependent man-
ner), for this to result in actual liver disease is very rare.39,44 There
is currently no conclusive evidence that statins cause renal dis-
ease or cognitive decline.44 On the other hand, statins may  cause
peripheral neuropathy, but the attributable risk is small (12 per
100,000 person-years).42 Of course, the effects of statins as mod-
ulators of the immune system may, in theory, have detrimental
systemic effects inﬂuencing the appearance of neurodegenerative
disorders, such as motor neurone disease, infections and cancer
development and progression.34 However, in a Danish cohort it was
shown that statins signiﬁcantly reduced mortality related to cancer
when compared to individuals who had never used statins.45
Increased incidence of type 2 diabetes mellitus (Type 2 DM)  is
a relatively newly identiﬁed statin adverse effect. The results of a
recent network meta-analysis suggested that, statins, as a class,
increased the risk of diabetes, particularly with more intensive
statin therapy.46 The frequency of Type 2 DM is mainly increased
in those with other elements of the metabolic syndrome or
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rediabetes such as obesity, glucose intolerance, and hypertension.
owever, it is thought that the beneﬁts from statins, as measured
y the number needed to treat for a reduction in myocardial infarc-
ion and stroke are much more favourable than the number needed
o harm from incident diabetes.39 Statin-induced interstitial lung
isease is another recognised side effect of statin therapy.47 The
echanism of lung injury is not deﬁned and it is thought that
iscontinuing the statin improves, and may  completely resolve,
ymptoms. Furthermore, in a recent study, amongst patients with
nterstitial lung disease, statin use was associated with reduced
ll-cause mortality.48
Of particular relevance to the use of statins in patients with
veitis are the potential ocular effects. A previous study has
hown a possible relationship between statin therapy and eye
uscle/movement disorders, speciﬁcally: diplopia, ptosis and
phthalmoplegia.49 A plausible mechanism by which these may
ccur is myositis of the extraocular muscles, the levator palpebrae
uperioris (upper eyelid) muscles, or both. The frequency of ocular
dverse events among the reported adverse drug reactions from the
ood and Drug Administration (FDA) and Adverse Drug Reactions
dvisory Committee (ADRAC) data has been recently published.50
mong 131,755 cases of patients taking statins, there were 2325
ases reported ocular adverse events after using statins (1.8%). The
ost highly reported ocular adverse events associated with statins
ere blurred vision (48.4%) and visual impairment (25.7%), how-
ver results indicated that the ocular problems formed a greater
roportion of the adverse events for subjects taking atorvastatin
2.1%).50 The use of statins in Age-Related Eye Diseases Study 2
AREDS2) trial participants was associated with cataract surgery
nd progression of both cortical and posterior subscapular type
ataracts.51 The risk of these outcomes seemed to be greater for
omen and patients under 75 years who used statins. The relation
etween serum lipids, statin use and the macular pigments in the
erum and retina, was examined in another study.52 The xantho-
hyll carotenoids lutein and zeaxanthin are found in and around
he macula of the retina, where they are termed macular pigment.
ietary lutein and zeaxanthin are absorbed with fat in the gut and
ransported on lipoproteins to the retina. Both macular pigment
nd serum lipoproteins have been related to risk for neurodegen-
rative diseases, such as age-related macular degeneration (AMD).
acular pigment optical density (MPOD) was not found to be lower
n statin users when compared to matched non-statin users, but
POD decreased signiﬁcantly with increased duration of statin
se.52 However, statin use was not statistically signiﬁcantly asso-
iated with progression to late AMD  in the AREDS2 participants,
nd these ﬁndings are consistent with ﬁndings in the majority of
revious studies.53
onclusions
The anti-inﬂammatory effects and immunomodulatory of
tatins are now widely accepted. This is supported by RCTs, which
ave demonstrated that further to their lipid-lowering ability,
tatins also exert anti-inﬂammatory effects in a wide variety of
isease states. Statins are well tolerated and have a favourable
ide effect proﬁle compared to other medications. However, further
esearch is required to clarify the impact of statins on ocular disease.
n RCT is currently underway to investigate the role of simvas-
atin as steroid-sparing agents in sight-threatening non-infectious
veitis. This data, in conjunction with experimental studies, should
ontribute to our understanding of the utility of statins in the man-
gement of sight-threatening ocular inﬂammatory disease.onﬂicts of interest
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